At present, diabetes is mainly treated with insulin injection and oral hypoglycemic drugs, and commonly used oral drugs mainly include insulin secretagogues, α-glucosidase inhibitors, insulin sensitizers, biguanides, etc. Although repeated and frequent subcutaneous injection of insulin can achieve the purpose of short-term hypoglycemia, it will also lead to some disadvantages, such as local infection, fat removal at the injection site, pressure, insulin resistance, etc., which will make patients feel uncomfortable and have poor compliance [5,6,7]. The gene discussed is INS; the disease is Hypoglycemia.